Circulating tumor cells : advances in liquid biopsy technologies / Richard J. Cote, Evi Lianidou, editors.

It is well recognized that blood could be the optimal site for evaluating cancer, allowing easy and repeated access for determining prognosis, establishing molecular targets, evaluating the efficacy of therapy, detecting the earliest signs of recurrence, and even detecting cancer at its earliest and...

Full description

Saved in:
Bibliographic Details
Other Authors: Cote, Richard J. (Editor), Lianidou, Evi (Editor)
Format: eBook
Language:English
Published: Cham, Switzerland : Springer, [2023]
Edition:Second edition.
Series:Current cancer research.
Subjects:
Online Access:Click for online access

MARC

LEADER 00000cam a22000007i 4500
001 on1392342762
003 OCoLC
005 20240909213021.0
006 m o d
007 cr cnu---unuuu
008 230805s2023 sz o 000 0 eng d
040 |a EBLCP  |b eng  |e rda  |c EBLCP  |d GW5XE  |d N$T  |d OCLCO  |d YDX  |d WSU  |d OCLCO  |d UKAHL  |d VLB  |d OCLCF 
019 |a 1394079087 
020 |a 9783031229039  |q electronic book 
020 |a 3031229037  |q electronic book 
020 |z 9783031229022 
024 7 |a 10.1007/978-3-031-22903-9  |2 doi 
035 |a (OCoLC)1392342762  |z (OCoLC)1394079087 
050 4 |a RC269  |b .C57 2023eb 
049 |a HCDD 
245 0 0 |a Circulating tumor cells :  |b advances in liquid biopsy technologies /  |c Richard J. Cote, Evi Lianidou, editors. 
250 |a Second edition. 
264 1 |a Cham, Switzerland :  |b Springer,  |c [2023] 
264 4 |c ©2023 
300 |a 1 online resource (xxi, 668 pages). 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a Current cancer research 
505 0 |a Part I Liquid Biopsy Technologies -- CTC-Based Liquid Biopsies and Diagnostic Leukapheresis -- Nuclease-Assisted Elimination of Wild-Type DNA -- Exploiting Exosomes for Cancer Diagnosis and Treatment -- Translational Opportunities of Extracellular Vesicles in Biomedicine -- Capture and Concentration of Circulating Cancer-Associated Extracellular Vesicles -- Circulating Tumor Cells (CTC) and Tumor-Derived Extracellular Vesicles (tdEV) -- Part II Technology Development -- Mathematical Oncology to Integrate Multimodal Clinical and Liquid Biopsy Data for the Prediction of Survival -- Microfluidics, CTC Capture, Analysis and Expansion -- Development and Validation of Molecular Assays for Liquid Biopsy Applications -- State of the Art in the Propagation of Circulating Tumor Cells -- Part III Biology -- Transcriptomic Analysis of CTCs -- Insight into Intratumoral Heterogeneity Through Single CTC Sequencing and CDX Analysis -- Molecular Characterization of Single Circulating Tumor Cells in Breast and Ovarian Cancer -- Circulating Tumour Cell Isolation and Molecular Profiling; Potential Therapeutic Intervention -- Dissecting the Molecular Profiles of Circulating Tumor Cells in Models of Breast and Prostate Cancers -- Part IV Clinical Application of the Liquid Biopsy Creating an Annotated Biospecimen Resource for Liquid Biopsy Applications -- Opportunities for Liquid Biopsies to Meet the Challenges of Precision Medicine -- Part V Prognosis and Therapeutic Monitoring -- CTCs in Early Breast Cancer -- NGS Analysis of Plasma cfDNA and cfmiRNA Signatures in Melanoma Brain Metastasis Patients -- ctDNA and Lung Cancer -- Clinical Perspectives in the Use of Liquid Biopsy in Metastatic Breast Cancer -- Circulating Tumor Cells in Men Treated for Prostate Cancer -- The Role of Liquid Biopsy in Brain Tumors -- Part VI The Next Frontier: Liquid Biopsy and Early Cancer Detection -- Early Cancer Detection: Challenges and Opportunities -- The Galleri Assay -- Index. 
504 |a Includes bibliographical references. 
520 |a It is well recognized that blood could be the optimal site for evaluating cancer, allowing easy and repeated access for determining prognosis, establishing molecular targets, evaluating the efficacy of therapy, detecting the earliest signs of recurrence, and even detecting cancer at its earliest and most curable stages. The analysis of cancer through blood samples is now known as the liquid biopsy and has been a rich source of research and clinical application. There has been an explosion of interest and progress in liquid biopsy technologies since the first edition of this book. The second edition will expand its focus to now include not only circulating tumor cells (CTC), but also other emerging aspects of the liquid biopsy, including circulating tumor DNA and methylated DNA (ctDNA, ct meDNA), ctRNA, ct miRNA, circulating tumor proteins (and other) biomarkers and circulating tumor derived exosomes (ctExosomes). 
588 |a Description based on online resource; title from digital title page (viewed on October 06, 2023). 
650 0 |a Cancer cells  |v Laboratory manuals. 
650 0 |a Tumors  |x Biopsy  |v Laboratory manuals. 
650 7 |a Cancer cells.  |2 fast  |0 (OCoLC)fst00845563 
655 7 |a Laboratory manuals.  |2 fast  |0 (OCoLC)fst01920776 
655 7 |a Laboratory manuals.  |2 lcgft 
655 7 |a Manuels de laboratoire.  |2 rvmgf 
700 1 |a Cote, Richard J.,  |e editor. 
700 1 |a Lianidou, Evi,  |e editor. 
776 0 8 |i Print version:  |a Cote, Richard J.  |t Circulating Tumor Cells  |d Cham : Springer International Publishing AG,c2023  |z 9783031229022 
830 0 |a Current cancer research. 
856 4 0 |u https://holycross.idm.oclc.org/login?auth=cas&url=https://link.springer.com/10.1007/978-3-031-22903-9  |y Click for online access 
903 |a SPRING-ALL2023 
994 |a 92  |b HCD